{"entity":{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","aka":["REGN4018"],"tldr":"Ubamatamab (REGN4018) is Regeneron's investigational MUC16×CD3 bispecific antibody, in phase 1/2 and phase 2 trials for ovarian and endometrial cancer.","summary":"Ubamatamab (REGN4018) is a bispecific antibody that binds MUC16 on tumour cells and CD3 on T cells and is designed to redirect T-cell killing towards MUC16-expressing cells. The first-in-human study NCT03564340 tests ubamatamab alone or with cemiplimab in recurrent ovarian cancer and other MUC16-positive cancers (phase 1/2); NCT06787612 is a multi-arm phase 2 platform study of ubamatamab combinations in platinum-resistant ovarian cancer; NCT04590326 combines it with the MUC16×CD28 costimulatory bispecific REGN5668; and NCT07154290 tests it with marlotamig in non-small-cell lung cancer. No results are recorded here; the registry entries and the cited abstracts are the sources.","status":"phase-2","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov: trials of Ubamatamab","url":"https://clinicaltrials.gov/search?intr=Ubamatamab"},{"label":"Ubamatamab phase 1/2 study design (JCO 2024, TPS5632)","url":"https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS5632"},{"label":"Ubamatamab translational study (Zhu et al., Clin Transl Sci 2024)","url":"https://doi.org/10.1111/cts.70082"},{"label":"ClinicalTrials.gov NCT03564340","url":"https://clinicaltrials.gov/study/NCT03564340"},{"label":"ClinicalTrials.gov NCT06787612","url":"https://clinicaltrials.gov/study/NCT06787612"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":["t-cell-engager"],"targets":["muc16","cd3"],"drugs":[],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04590326","nct03564340","nct06787612","nct07154290"],"people":[],"bottlenecks":[],"keyPapers":["paper-zhu-clin-transl-sci"],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo maintainers (issue #46)","editedOn":"2026-09-21","note":"Ingested from ClinicalTrials.gov v2 (registry-only) on 2026-09-16; mechanism and targets checked on 2026-09-21 against the NCT03564340 official title, the JCO 2024 TPS5632 study-design abstract and Zhu et al., Clin Transl Sci 2024."},"modality":"Bispecific T-cell engager (MUC16×CD3)","mechanism":"Bispecific antibody that binds MUC16 on tumour cells and CD3 on T cells, bringing them together to promote T-cell-mediated killing of MUC16-expressing cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ubamatamab/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"trial":[{"id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/"},{"id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/"},{"id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/"},{"id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/"}],"paper":[{"id":"paper-zhu-clin-transl-sci","kind":"paper","name":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer","route":"/key-papers/paper-zhu-clin-transl-sci/"}]}}